Hims Q1 Earnings: The Branded Pivot's First Test

What happened

Hims & Hers reports Q1 2026 earnings tonight, with the stock up ~45% from its February low as investors buy into the Novo Nordisk branded GLP-1 partnership. The quarter is the first clean read on the transition from compounded semaglutide to FDA-approved Wegovy/Ozempic, which is the core of the company's recovery narrative. The DeepValue report warns that the stock at 46x P/E offers no margin of safety, and the Q1 print must show gross margin stabilizing near 72% and marketing efficiency holding at 39% of revenue to justify the rally. Underneath the optimism, unresolved SEC and DOJ investigations into prior marketing practices create binary downside risk if enforcement actions emerge. Tonight's results will either validate the recovery thesis or expose that the branded transition is more costly and slower than the market expects.

Implication

If Q1 shows gross margin ~72% and branded GLP-1 volume ramping, the bull case gains traction and the stock may hold recent gains. However, any miss or regulatory headline could drive a sharp re-rating toward the $18 bear case.

Thesis delta

The thesis shifts from 'wait for proof of branded transition' to 'proof arrives tonight.' Q1 results are the make-or-break catalyst: a clean print would strengthen the recovery narrative, while margin weakness or regulatory news would confirm that the stock's 45% rally was premature and overvalued.